Kurt Anker Nielsen (b. 1945)
Joined the Board in April 2006.
Chairman of the Audit Committee.
Position
Director
Competencies
| Education: | ||
| 1972 | MSc (Economics and Business Administration), Copenhagen Business School (Denmark) | |
| Former positions: | ||
| 1972–1973 | Business Economist, Carlsberg A/S (Denmark) | |
| 1973–1974 | Management Consultant, Booz, Allen and Hamilton of Scandinavia (Denmark) | |
| 1974–1977 | Economist, Novo Industri A/S (Denmark) | |
| 1977–1984 | Head of Corporate Planning, Novo Industri A/S (Denmark) | |
| 1984–1985 | Director, Corporate Planning and Communications, Novo Industri A/S (Denmark) | |
| 1985–1989 | Vice President Corporate Finance, Novo Industri A/S (Denmark) | |
| 1989–2000 | Chief Financial Officer, Novo Nordisk A/S (Denmark) | |
| 1996–2000 | Deputy CEO, Novo Nordisk A/S (Denmark) | |
| 2000–2003 | CEO, Novo A/S (Denmark) | |
Fiduciary positions
Chairman of the Board of: Reliance A/S (Denmark).
Deputy Chairman of the Board of: Novozymes A/S (Denmark).
Member of the Boards of: Lifecycle Pharma A/S (Denmark), Novo Nordisk A/S (Denmark), Novo Nordisk Fonden (Denmark) and ZymoGenetics Inc. (USA).
Positions of trust
Chairman of: LifeCycle Pharma A/S’ Audit Committee (Denmark), Novo Nordisk A/S’ Audit Committee (Denmark), Novozymes A/S’ Audit Committee (Denmark) and ZymoGenetics Inc.’s Audit Committee (USA).